Prothena (GB:0Y3M)
LSE:0Y3M

Prothena (0Y3M) Share Price & Analysis

0 Followers

0Y3M Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$25.27 - $79.16
Previous Close$68.16
Volume25.00
Average Volume (3M)221.00
Market Cap
$3.64B
Enterprise Value$2.96B
Total Cash (Recent Filing)$686.20M
Total Debt (Recent Filing)$4.88M
Price to Earnings (P/E)-25.9
Beta-0.80
Aug 08, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.63
Shares Outstanding52,751,775
10 Day Avg. Volume0
30 Day Avg. Volume221
Standard Deviation0.21
R-Squared0.04
Alpha-0.00625
Financial Highlights & Ratios
Price to Book (P/B)5.77
Price to Sales (P/S)267.53
Price to Cash Flow (P/CF)-18.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue53.88
Enterprise Value/Gross Profit54.89
Enterprise Value/Ebitda-20.61
Forecast
Price Target Upside24.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10


Financials

Annual

0Y3M FAQ

What was Prothena’s price range in the past 12 months?
Prothena lowest share price was $25.27 and its highest was $79.16 in the past 12 months.
    What is Prothena’s market cap?
    Currently, no data Available
    When is Prothena’s upcoming earnings report date?
    Prothena’s upcoming earnings report date is Aug 08, 2023 which is in 64 days.
      How were Prothena’s earnings last quarter?
      Prothena released its earnings results on May 04, 2023. The company reported -$0.89 earnings per share for the quarter, missing the consensus estimate of -$0.871 by -$0.019.
        Is Prothena overvalued?
        According to Wall Street analysts Prothena’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Prothena pay dividends?
          Prothena does not currently pay dividends.
          What is Prothena’s EPS estimate?
          Prothena’s EPS estimate is -$0.96.
            How many shares outstanding does Prothena have?
            Prothena has 52,751,774 shares outstanding.
              What happened to Prothena’s price movement after its last earnings report?
              Prothena reported an EPS of -$0.89 in its last earnings report, missing expectations of -$0.871. Following the earnings report the stock price went up 14.364%.
                Which hedge fund is a major shareholder of Prothena?
                Among the largest hedge funds holding Prothena’s share is Maple Rock Capital Partners Inc.. It holds Prothena’s shares valued at 14M.

                  ---

                  Prothena Stock Smart Score

                  The Prothena Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Prothena

                  Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Biogen
                  Gilead Sciences
                  Illumina
                  Prothena

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis